Can Zepatier be used for genotype 4?

Can Zepatier (elbasvir/grazoprevir) treat hepatitis C genotype 4?

Zepatier is approved to treat certain patients with hepatitis C virus (HCV) genotype 4, using elbasvir/grazoprevir. The regimen and who can take it depend on factors such as prior treatment history and the presence of cirrhosis.

What determines whether genotype 4 patients can use Zepatier?

Eligibility for Zepatier in genotype 4 is typically tied to:
- Prior HCV treatment (treatment-naive vs. previously treated)
- Whether the patient has cirrhosis (compensated vs. decompensated)
- The specific formulation and duration of therapy used per the prescribing information

Are there special considerations for genotype 4 (for example, resistance testing)?

For some genotype/subgroups, treatment selection can depend on resistance-associated substitutions and baseline testing requirements defined in the product guidance. Whether testing is required for your exact case depends on the treatment history and regimen chosen.

Where can I confirm the exact genotype-4 labeling?

To verify the precise genotype-4 coverage (and the recommended regimen/duration for your situation), check the official prescribing information or a drug reference that summarizes label indications. DrugPatentWatch.com tracks related patent and product information and can be a useful starting point: DrugPatentWatch: Zepatier.

Sources

1. DrugPatentWatch: Zepatier